-
公开(公告)号：KR1020140108411A
公开(公告)日：2014-09-11
申请号：KR1020130020953
申请日：2013-02-27
Applicant: 한림대학교 산학협력단
CPC classification number: A61K38/08 , A61K38/10 , A61K38/16 , C07K7/06 , C07K7/08 , C07K14/00 , C12N15/62
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating inflammatory arthritis, and more specifically, to a pharmaceutical composition for preventing or treating inflammatory arthritis containing fusion protein of FK506 binding protein which can go through the inside of cartilaginous tissue as an active ingredient.
Abstract translation: 本发明涉及用于预防或治疗炎症性关节炎的药物组合物，更具体地说，涉及一种用于预防或治疗含有可通过软骨组织内作为活性成分的FK506结合蛋白的融合蛋白的炎症性关节炎药物组合物。
-
公开(公告)号：KR1020140012428A
公开(公告)日：2014-02-03
申请号：KR1020120079316
申请日：2012-07-20
Applicant: 한림대학교 산학협력단 , (주)바이오웰스
CPC classification number: A61K38/08 , A61K38/10 , A61K38/16 , C07K7/06 , C07K7/08 , C07K14/00 , C12N15/62 , Y10S514/866
Abstract: The present inventors developed a glyoxalase (GLO) fusion protein expression vector. This expression vector was used to over-express the GLO fusion protein, which was then purified by using Ni^2+ affinity chromatography columns. Western blotting confirmed that the GLO fusion protein purified in the cultured insulin-secreting cells was delivered to cells in a concentration and time dependent manner. The GLO fusion protein permeating the cells was continuously maintained 48 hours in the cells. In addition, it was seen that the GLO fusion protein permeating the cells effectively inhibited cell death due to sodium nitroprusside (SNP) and DNA fragmentation. It was verified through histological staining, blood glucose level testing, and blood testing, that the GLO fusion protein effectively inhibited diabetes even in a diabetic animal model using streptozotocin (STZ). These results mean that the GLO fusion protein permeates the insulin-secreting cells and the GLO function is well conducted in the cells. Therefore, the GLO fusion protein can be applied as an agent for treating diabetic diseases and diabetic complications.
Abstract translation: 本发明人开发了乙二醛酶（GLO）融合蛋白表达载体。 该表达载体用于过表达GLO融合蛋白，然后使用Ni ^ 2 +亲和色谱柱进行纯化。 Western印迹证实，在培养的分泌胰岛素的细胞中纯化的GLO融合蛋白以浓度和时间依赖性方式递送至细胞。 将透过细胞的GLO融合蛋白在细胞中连续保持48小时。 此外，可以看出，穿透细胞的GLO融合蛋白有效地抑制了硝普钠（SNP）和DNA片段化引起的细胞死亡。 通过组织学染色，血糖水平测试和血液检测证实，即使在使用链脲霉素（STZ）的糖尿病动物模型中，GLO融合蛋白也能有效抑制糖尿病。 这些结果意味着GLO融合蛋白渗透胰岛素分泌细胞，GLO功能在细胞中很好地进行。 因此，GLO融合蛋白可用作治疗糖尿病和糖尿病并发症的药剂。
-
公开(公告)号：KR1020140010536A
公开(公告)日：2014-01-27
申请号：KR1020120076387
申请日：2012-07-13
Applicant: 한림대학교 산학협력단
CPC classification number: A61K38/1709 , C07K14/47 , C12N15/62 , Y10S514/886
Abstract: Refined SIRT2 fusion protein is penetrated into a Raw 264.7 cell in a time and injection amount dependent way, and protects the cell from cell death and cytotoxicity induced by lipopolysaccharide and hydrogen peroxide. The penetrated SIRT2 fusion protein also controls the activation of NF-kB and MAPKs (mitogen-activated protein kinases), and the expression of cytokine.
Abstract translation: 精制的SIRT2融合蛋白以时间和注射量依赖的方式穿透到Raw 264.7细胞中，并保护细胞免受细胞死亡和由脂多糖和过氧化氢诱导的细胞毒性。 穿透的SIRT2融合蛋白也控制NF-kB和MAPK（丝裂原活化蛋白激酶）的活化以及细胞因子的表达。
-
公开(公告)号：KR1020130134530A
公开(公告)日：2013-12-10
申请号：KR1020120058107
申请日：2012-05-31
Applicant: 한림대학교 산학협력단
CPC classification number: A61K38/177 , Y10S530/839
Abstract: Phosphoprotein enriched in astrocytes-15 (PEA-15) is a small protein created in neurons or astrocytic cells in brain. This protein which is a multi-functional protein can increase the cell survival rate thanks to its antiapoptotic and proapoptotic properties. Parkinson's disease is a neurodegenerative disease that dopamine neurons are reduced in substantia nigra in brain. The inventers found out that PEP-1-PEA-15 fusion protein can protect dopamine neurons from oxidation stress in SH-SY5Y neuroblastom cells and animals suffering from Parkinson's disease. It is confirmed that PEP-1-PEA-15 fusion protein can be transferred to SH-SY5Y cells and substantia nigra through western blot analysis. PEP-1-PEA-15 fusion protein prevents the active oxygen species production DNA tessellation induced to MPP+ and induces SH-SY5Y cell survival. Transmitted PEP-1-PEA-15 fusion protein improves the expression level of Bcl-2 protein but reduces the impression level of Bax protein. Also, PEP-1-PEA-15 fusion protein is transmitted to substantia nigra and prevents dopamine neuron cell death in substantia nigra. Therefore, PEP-1-PEA-15 fusion protein can prevent and treat Parkinson's disease.
Abstract translation: 富含星形胶质细胞-15（PEA-15）的磷酸蛋白是在脑中神经元或星形细胞细胞中产生的小蛋白质。 作为多功能蛋白质的蛋白质可以通过其抗细胞凋亡和促凋亡性质而增加细胞存活率。 帕金森病是神经退行性疾病，多巴胺神经元在脑黑质中减少。 发明人发现PEP-1-PEA-15融合蛋白可以保护多巴胺神经元免受SH-SY5Y神经母细胞和帕金森病动物的氧化应激。 证实通过western印迹分析可以将PEP-1-PEA-15融合蛋白转移至SH-SY5Y细胞和黑质。 PEP-1-PEA-15融合蛋白可阻止活性氧生成诱导MPP +的DNA镶嵌，诱导SH-SY5Y细胞存活。 转染的PEP-1-PEA-15融合蛋白提高了Bcl-2蛋白的表达水平，降低了Bax蛋白的印象。 此外，PEP-1-PEA-15融合蛋白传播到黑质，并防止黑质中的多巴胺神经元细胞死亡。 因此，PEP-1-PEA-15融合蛋白可以预防和治疗帕金森病。
-
15.发明公开
公开(公告)号：KR1020120119561A
公开(公告)日：2012-10-31
申请号：KR1020110037572
申请日：2011-04-22
Applicant: 한림대학교 산학협력단
CPC classification number: A61K47/64 , A23L33/17 , A61K8/64 , A61K47/22 , Y10S514/824 , Y10S514/885 , Y10S514/886
Abstract: PURPOSE: An increase method of fused protein into living cells or organs by adding levosulpiride to fused protein in which protein transport domains and therapeutic protein are covalently bonded is provided to increase therapeutic effects of protein medicines for various diseases. CONSTITUTION: An increase method of fused protein into living cells or organs is processed by adding levosulpiride to fused protein in which protein transport domains and therapeutic protein are covalently bonded. The levosulpiride is primarily processed in the living cells or organs than the fused protein. A protein transport domain is Tat, PEP-1, oligolysine, oligo arginine or oligo(lysine and arginine). The therapeutic protein is rpS3. A composition for preventing and treating inflammatory diseases comprises fused proteins in which is covalently bonded with the protein transport domain and levosulpiride. The inflammation therapeutic protein is rpS3. A composition for preventing and improving skin external application comprises fused proteins in which is covalently bonded with the protein transport domain and levosulpiride.
Abstract translation: 目的：提供蛋白质转运区域和治疗性蛋白质共价键合的融合蛋白中的左半乳糖苷加入活细胞或器官中的融合蛋白的增加方法，以增加蛋白质药物对各种疾病的治疗效果。 构成：将融合蛋白加入到活细胞或器官中的增加方法是通过将蛋白质转运结构域和治疗性蛋白质共价结合的融合蛋白中加入左美沙比来进行加工。 左氧氟沙棱主要在活体细胞或器官中处理，而不是融合蛋白。 蛋白质转运结构域是Tat，PEP-1，寡聚赖氨酸，寡聚精氨酸或寡聚（赖氨酸和精氨酸）。 治疗性蛋白质是rpS3。 用于预防和治疗炎性疾病的组合物包括其中与蛋白质转运结构域和左旋舒巴比妥共价键合的融合蛋白。 炎症治疗蛋白是rpS3。 用于预防和改善皮肤外用的组合物包括其中与蛋白质转运结构域和左旋肉碱共价结合的融合蛋白。
-
Patent Agency Ranking
公开(公告)号：KR1020120051192A
公开(公告)日：2012-05-22
申请号：KR1020100112498
申请日：2010-11-12
Applicant: 한림대학교 산학협력단
CPC classification number: C12N9/0051 , A61K8/64 , A61K38/44 , A61K47/64 , A61Q19/00 , C07K7/06 , C07K7/08 , C07K2319/01 , C12Y108/98002
Abstract: PURPOSE: A composition containing cell permeable sulfiredoxin fusion proteins is provided to suppress and treat inflammation in an animal experiment. CONSTITUTION: A sulfiredoxin fusion protein contains 9-15 amino acid residues. A transduction domain is HIV Tat 49-57 residues, oligolysine, oligoarginine, or oligo(lysine,arginine). The fusion protein has an amino acid sequence of sequence number 7, 9, or 11. A recombinant polypeptide encoding the fusion protein has a transduction domain coding oligonucleotide sequence at one end of sulfiredoxin coding cDNA. A pharmaceutical composition for used as a therapeutic agent for preventing and treating inflammatory dermatitis contains the fusion protein as an active ingredient and pharmaceutically acceptable carrier.
Abstract translation: 目的：提供一种含有细胞可渗透的磺酰氧还蛋白融合蛋白的组合物，用于抑制和治疗动物实验中的炎症。 构成：硫氧还蛋白融合蛋白含有9-15个氨基酸残基。 转导结构域是HIV Tat 49-57残基，寡聚赖氨酸，寡精氨酸或寡聚（赖氨酸，精氨酸）。 融合蛋白具有序列号7,9或11的氨基酸序列。编码融合蛋白的重组多肽在硫氧还蛋白编码cDNA的一端具有转导结构域编码寡核苷酸序列。 用作预防和治疗炎症性皮炎的治疗剂的药物组合物含有作为活性成分的融合蛋白质和药学上可接受的载体。
-
公开(公告)号：KR1020120040308A
公开(公告)日：2012-04-27
申请号：KR1020100101645
申请日：2010-10-19
Applicant: 한림대학교 산학협력단
CPC classification number: A61K38/16 , C07K14/00 , C12N15/62 , Y10S514/857
Abstract: PURPOSE: A composition containing cell transducing rpS3 fusion protein is provided to smoothly deliver the protein into skin cells and to effectively suppress inflammation. CONSTITUTION: A pharmaceutical composition for preventing and treating skin inflammatory diseases contains cell transducing rpS3 fusion protein as a main ingredient. The fusion protein has a non-hyphophilic domain containing 5 or more tryptophane, a hydrophilic domain containing 4 or more lysine, and protein transduction domain with a spacer which divides two domains. A cosmetic composition for treating skin inflammation contains 15-30 amino acids.
Abstract translation: 目的：提供含有细胞转导rpS3融合蛋白的组合物，以平滑将蛋白质输送到皮肤细胞中并有效抑制炎症。 构成：用于预防和治疗皮肤炎症性疾病的药物组合物含有细胞转导rpS3融合蛋白作为主要成分。 该融合蛋白具有含有5个或更多个色氨酸的非亲和结构域，含有4个或更多个赖氨酸的亲水结构域和具有划分两个结构域的间隔物的蛋白质转导结构域。 用于治疗皮肤炎症的化妆品组合物含有15-30个氨基酸。
-
公开(公告)号：KR1020120035566A
公开(公告)日：2012-04-16
申请号：KR1020100097161
申请日：2010-10-06
Applicant: 한림대학교 산학협력단
CPC classification number: A61K38/1709 , C07K14/47 , C12N15/62 , Y10S514/824
Abstract: PURPOSE: A pharmaceutical composition containing cell permeable rpS3 fusion protein is provided to smoothly deliver rpS3 fusion proteins into neural cells and to prevent the neural cells from apoptosis. CONSTITUTION: A pharmaceutical composition for preventing and treating neural diseases contains a cell permeable rpS3 fusion protein having a protein transduction domain linked to at least one end among N-terminal and C-terminal of rpS3 protein by covalent bond. The protein transduction domain comprises: a non-hydrophilic domain containing 15-30 amino acids and 5 or more tryptophans; a hydrophilic domain containing 4 or more lysines; and a spacer which separates two domains the rpS3 fusion protein has an amino acid sequence of sequence number 7, 9, or 11.
Abstract translation: 目的：提供含有细胞渗透性rpS3融合蛋白的药物组合物，以将rpS3融合蛋白顺利递送至神经细胞，并防止神经细胞凋亡。 构成：用于预防和治疗神经疾病的药物组合物含有通过共价键在rpS3蛋白的N末端和C末端连接至少一端的蛋白转导结构域的细胞可渗透的rpS3融合蛋白。 蛋白质转导结构域包含：含有15-30个氨基酸和5个或更多个色氨酸的非亲水结构域; 含有4个或更多赖氨酸的亲水结构域; 和分离两个结构域的间隔区，rpS3融合蛋白具有序列号7,9或11的氨基酸序列。
-
公开(公告)号：KR1020110127324A
公开(公告)日：2011-11-25
申请号：KR1020100046741
申请日：2010-05-19
Applicant: 한림대학교 산학협력단 , 인하대학교 산학협력단 , 대한민국(농촌진흥청장)
CPC classification number: A61F2/02 , A61L27/227 , C08J3/205 , C08L89/00
Abstract: PURPOSE: An artificial dura mater and a manufacturing method thereof are provided to guarantee safety in operation and to do not cause inflammation in the operation. CONSTITUTION: Silk fibroin aqueous solution is cast in smooth and flat place and is dried. The crystallization induction of the dried silk fibroin is executed. A crystallization induction step puts the dried silk fibroin is executed into an enclosure container in which relative humidity is over 80% and executes annealing with water.
Abstract translation: 目的：提供人造硬膜及其制造方法，以保证手术中的安全性，并且不会在手术中引起炎症。 构成：将丝素蛋白水溶液浇铸在光滑平坦的地方，并干燥。 干燥的丝素蛋白的结晶诱导被执行。 结晶诱导步骤将干燥的丝素蛋白进行到相对湿度超过80％的封闭容器中，并用水进行退火。
-
公开(公告)号：KR101732349B1
公开(公告)日：2017-05-04
申请号：KR1020150131419
申请日：2015-09-17
Applicant: 한림대학교 산학협력단
Abstract: 파킨슨병은뇌의흑색질내에서도파민뉴런이점차상실되는신경퇴행성질환이다. 본발명자들은 PIM2 융합단백질이 SH-SY5Y 신경아세포종세포및 파킨슨병동물모델에서산화스트레스로부터도파민뉴런을보호할수 있음을밝혀내었다. PIM2 융합단백질은 SH-SY5Y 세포내로그리고뇌의흑색질내로잘 이동함을웨스턴블랏분석으로확인하였다. PIM2 융합단백질은 MPP로유도되는활성산소종생성및 DNA 단편화를현저히저해하였으며, 결과적으로 SH-SY5Y 세포의생존을유도했다. 나아가, TH 항체및 크레실바이올렛염색을이용한면역조직화학분석데이타는 PIM2 융합단백질이 MPTP와같은산화스트레스에대하여흑색질내의도파민세포를현저히보호함을나타낸다. 따라서, PIM2 융합단백질은파킨슨병의예방및 치료용도로이용가능하다.
-
-
-
-
-
-
-
-
-
Search Results
106
records
(took 0.032 seconds)
